OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kazmi on Tailoring Treatment to Various Subtypes of CRC

March 19th 2021

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

Dr. Hanna on Approaching Biomarker Testing in Lung Cancer

March 18th 2021

Nasser H. Hanna, MD, discusses his approach to biomarker testing in lung cancer.

Dr. George on Actionable Pathogenic Variants in Adults With Breast or Ovarian Cancers in the Caribbean

March 18th 2021

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

Dr. Hurley on Breast Cancer Baseline Characteristics in the Caribbean Vs the United States

March 18th 2021

Judith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.

Dr. Choueiri on the CheckMate-9ER Exploratory Analysis in Advanced RCC

March 18th 2021

Toni K. Choueiri, MD, discusses results from an exploratory analysis of the phase 3 CheckMate-9ER trial in patients with advanced renal cell carcinoma.

Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer

March 18th 2021

Benjamin P. Levy, MD, discusses the importance of testing for KRAS mutations in lung cancer.

Dr. Martin on Determining Transplant Eligibility in Multiple Myeloma

March 18th 2021

Thomas G. Martin, MD, discusses factors that can inform transplant eligibility in multiple myeloma.

Dr. Salem on the FDA Approval of Y-90 Glass Microspheres for HCC

March 18th 2021

Riad Salem, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microsphere in March 2021 for the treatment of patients with hepatocellular carcinoma.

Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer

March 17th 2021

Alexander Spira, MD, PhD, FACP, discusses the role of broad molecular testing in lung cancer.

Dr. Till on the Durability of Response With Brexucabtagene Autoleucel in MCL

March 16th 2021

Brian Till, MD, discusses the potential durability of brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Atkins on the FDA Approval of Tivozanib in Relapsed/Refractory Advanced RCC

March 16th 2021

Michael B. Atkins, MD, discusses the FDA approval of tivozanib in relapsed/refractory advanced renal cell carcinoma.

Dr. Martin on the Utility of Aggressive Frontline Treatment in Multiple Myeloma

March 15th 2021

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL

March 12th 2021

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Dr. Kumar on the Challenges of Selecting Therapy in Heavily Pretreated Multiple Myeloma

March 12th 2021

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Dr. Mead on the Role of BTK Inhibition After Venetoclax in Relapsed/Refractory CLL

March 12th 2021

Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.

Dr. Philip on Non-Operative Treatment Advances in CRC

March 12th 2021

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

Dr. Kazmi on Choosing Among Regorafenib and TAS-102 in Metastatic CRC

March 11th 2021

Syed Kazmi, MD, discusses choosing among regorafenib and TAS-102 in the treatment of patients with metastatic colorectal cancer.

Dr. Bociek on the Role of MRD in CLL

March 11th 2021

R. Gregory Bociek, MD, discusses the role of minimal residual disease in patients with chronic lymphocytic leukemia.

Dr. Au on the Rationale to Evaluate Antiviral Immunity From COVID-19 in Cancer

March 11th 2021

Lewis Au, MBBS, BMedSci, FRACP, discusses the rationale to evaluate antiviral immunity from COVID-19 among patients with cancer.

Dr. Richardson on the Toxicity Profile of Melphalan Flufenamide in Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.